Synthego, the genome engineering company, today announced the launch of Eclipse™, a new high-throughput cell engineering platform designed to accelerate drug discovery and validation by providing highly predictable CRISPR-engineered cells at scale through the integration of engineering, bioinformatics, and proprietary science. The launch of this unique CRISPR-based platform is driving the company’s growing impact in biopharma R&D, reinforcing Synthego’s position as the genome engineering leader.
CRISPR-engineered cells have a wide range of applications in research and development across disease areas, including in neuroscience and oncology. Synthego created the Eclipse Platform to enhance disease modeling, drug target identification and validation, and accelerate cell therapy manufacturing.
"By industrializing cell engineering, Synthego’s Eclipse Platform will enable economies of scale, turning a historically complex process into one that is flexible, reliable, and affordable,” said Bill Skarnes, Ph.D., professor and director of Cellular Engineering at The Jackson Laboratory and Synthego advisory board member. “Offering CRISPR ...
